CKD and CVD - FOMA District 2 · CKD and CVD • CKD is an independent risk for all types of CVD...
Transcript of CKD and CVD - FOMA District 2 · CKD and CVD • CKD is an independent risk for all types of CVD...
CKD and CVD
• Jamal Salameh, MD, FACP, FASN
First Coast Nephrology
An Epidemic of Kidney Disease
Clinical Practice Guidelines for CKD Am J Kidney Dis. 2002;39(suppl 1):S17–S31.
GFR = glomerular filtration rate (mL/min/1.73 m2); *with kidney damage
Stage 1: GFR ≥90*
Stage 3: GFR 30–59
Stage 4: GFR 15–29
Stage 2: GFR 60–89*
Stage 5: GFR <15
n=5,900,000
n=5,300,000
n=7,600,000
n=400,000
n=300,000
Total=23 million USA
Prevalence CKD stages 1- 4
10% 1988-94
13% 1999-2004 Coresh, JAMA 298:2038, 2007
Scope of Disease: NHANES data
Figure 1.1 (Volume 1)
NHANES participants age 20 & older.
USRDS Annual Data Report 2011 Fig 1.1, Vol 1
CKD and CVD
• CKD is an independent risk for all types of CVD
• In addition, CKD is associated c adverse outcomes in patients c CVD
• This includes an inc M/M in CAD, PCI, CABG, PTA, CHF, PVD and arrhythmias (not discussed)
• Both a decrease in GFR and Proteinuria independently increase risk of CVD
KDIGO controversies conference KI 80:17-28, 2011
Albuminuria and GFR affect mortality and CKD outcomes
CKD predicts CV events: HOPE study
Mann et al. Ann Intern Med 2001;134:629–636
0
10
20
30
40 All patients
Patients taking placebo
Patients taking ramipril
Creatinine
<124 µmol/l Creatinine
≥124 µmol/l
n=8307
n=908 Events per
1000
person
years
HOPE=Heart Outcomes and
Prevention Evaluation study
Rates of death and cardiovascular events rise
as renal function declines
1.0
8 4.7
6
11
.36
14
.14
21
.8
36
.6
0.7
6
11
.29
3.6
5
2.1
1
0
10
20
30
40
>60 45-59 30-44 15-29 <15
Ag
e-s
tan
dard
ised
rate
per
100 p
ers
on
years
Death from any cause
Cardiovascular events
Go et al et al. NEJM 2004 23: 351(13): 1296-1305
Estimated GFR (ml/min/1.73 m2)
25-34 35-44 45-54 55-64 65-74 75-84 >85
Age
An
nu
al m
ort
ality
(%
)
Adapted from Levey AS et al. Am J Kidney Dis 1998; 32: 853-906.
Cardiovascular Mortality Rates are Higher among Dialysis Patients
General
population: male
General
population:
female
Dialysis: male
Dialysis: female
10
100
1
0.01
0.1
0.001
CKD and CVD
• Spectrum of disease:
-CAD (Angina/ACS)
-CHF
-CVA
-PVD
-SCD (Sudden Cardiac Death)
Prevalence of Co-morbidity and Level of GFR
%
GFR 60 ml/min
GFR <60 ml/min
DM CHF Stroke/
TIA
PVD Any
CVD
IHD
0
5
10
15
20
25
30
35
40
GFR 60
GFR< 60
CKD and CAD
• Incidence/Severity of CAD inc c dec GFR
• In pts c CAD, CKD worsens prognosis
• Pattern of Diffuse Multivessel dz
• Incidence approaches or > 50% in ESRD pts
• M/M are Inversely assoc c Dec GFR
• Typical Risk Factors are common in CKD
Cardiovascular diseases in CKD
patients
Damage to the heart
(Uremic cardiomyopathy)
Damage to the
arteries
(Uremic arteriopathy)
CKD and CAD
• Typical Risks include:
-Age (>55 M and >65 F)
-Sex (Male)
-Dyslipidemia (Inc LDL, Low HDL)
-Smoking
-FHx of CAD
CKD and CAD
• Traditional Risk Factors for CAD
-HTN
-DM
-LVH
-Sedentary Lifestyle
-Menopause
-Obesity
CKD Screening in the Primary Care Population: Who is “At Risk”
National Kidney Foundation Kidney Disease Outcome Quality Initiative: • NKF KDOQI • Provides evidence-based
clinical practice guidelines
CKD and CAD
• Non Traditional Risk Factors for CAD:
-Albuminuria
-Hyperhomocysteinemia
-Anemia
-Abnl Ca and PO4 metabolism-Vasc Ca++
-ECF Overload
-Inflammation
-Lipoprotein abnormalities
Cardiovascular Disease in CKD : Multifactorial Pathogenesis
Cardiovascular
Disease Chronic
inflammation
Exogenous
vitamin
D/deficit
Oxidative
stress
Duration of
dialysis Elevated PTH/
2°HPT
Hypertension
Dyslipidemia
Diabetes
Mellitus
Genetics
Increased homocysteine
levels
Elevated Ca ×
P product
Exogenous Ca
intake
Hyperphos-
phatemia
Smoking
Traditional risk factors
Non Traditional risk factors
Patients New to Dialysis and Established Patients
Prevalence of Vascular Calcification in CKD
40%
57%
83%
0%
20%
40%
60%
80%
100%
Russo et al RIND TTG
*Russo et al AJKD 2004 (CrCl =33 ml/min) **Spiegel D et al. Hemod Internat 2004: 8:265 ***Chertow et al KI 2002
*
**
***
Stage 3-4 CKD
Probability of All-Cause Survival According to Calcification Status
*Comparison Between Curves Was Highly Significant (x2=42.66, P<0.0001)
Source: Blacher A, et al. Hypertension:938-942, October 2001
Pro
bab
ilit
y o
f S
urv
ival
0.00
0.25
0.50
0.75
1.00
Duration of Follow-Up (Months)
0 20 40 60 80
Calcification Score: 0
Calcification Score: 1
Calcification Score: 2
Calcification Score: 3
Calcification Score: 4
Serum Phosphorus and Mortality
in Hemodialysis Patients
1.50
1.00 1.00 1.08
1.25
1.42
1.68
2.03
0
0.5
1
1.5
2
2.5
<3 3-4 4-5 5-6 6-7 7-8 8-9 >9
Serum Phosphorous Concentration (mg/dL)
Rela
tive R
isk o
f D
eath
*
n = 40,538
P < 0.0001
*Multivariable Adjusted Block G, J Am Soc Neph 15: 2208-2218, 2004
CKD and CAD
CKD and CAD
CKD and CAD
• Treatment:
-ASA
-Clopidogrel
-B Blockers
-ACE I/ARB’s
-Statins (not much data in ESRD x SHARP)
-PCI
-CABG (Conflicting data re PCI vs CABG)
CKD and CHF
• CHF Increases c Declining GFR
• CHF is Leading CV condition in CKD
• Common etiologies are Pressure/Volume XS
• Myocardial Interstitial Fibrosis (RAAS/SNS/Endothelin/ADH/TGF/IL1/TNF..)
Synergistic effect of CKD, CHF and Anemia as risk factors for Death
Collins, Adv studies in Med 2003
2 yr mortality (n~ 200,000 5% Medicare sample)
%
CKD and CHF
CKD and CHF
• Treatment:
-Na restriction
-Diuretics (usually higher doses) and UF
-ACE I/ARB’s
-BB (Carvedilol, Metoprolol, Bisoprolol)
-Anemia Tx
-Ca and Phos Tx to prevent Calcifications
CKD and CVA
• Independent risk for ICH and Ischemic-RR=1.4
• ESRD pts have a 5-10 risk of age match population to equal approx 4%/year
• Most CVA ischemic 87% in CHOICE study (enrolled 78% ESRD pts and rest CKD 5)
• Approximately 33% during or just p HD
• Mortality approx 35%, much higher than non
HD population, compared to 12% for CKD only
CKD and CVA
• Treatment:
-Tx HTN
-Antiplatelets
-Statin rx (controversy in ESRD x SHARP)
-CEA in ipsilateral high grade dz
CKD and PVD
• CKD independent risk factor for PVD
• NHANES reported prevalence of 24% in CKD
• Other studies report 7% to 48% prevalence
• Worse stage/GFR yields worse dz
• High rate traditional risk factors in CKD pts
• Nontraditional risk factors abound too
CKD and PVD
• Treatment:
-Antiplatelets
-Smoking cessation
-Plavix not studied in CKD population
-Cilostazol helped in ESRD pts
-Statins (as discussed prior)
-PTA vs Bypass (ESRD pts may?? do better c
PTA)
CKD and SCD
• SCD defined as sudden death, unexpected
within an hour of Sx onset
• Accounts for 25% of death in ESRD pts
• Annual rate of 5.5% per year
• Survival is quite poor at 3-11% at 6 mos
• SCD incrementally increases c decreasing GFR
• ESRD pts die from SCD > ACS
• CKD pts die from ACS > SCD
Epidemiology of SCD : CKD populations
• CKD stages 3-5 (not dialysis) SCD risk ↑ by HR of 1.1 for every 10ml/min decline in eGFR
• Event rate 0.8% per yr in non-dialysis CKD
• In non-diabetic dialysis patients, rate is 7% in 1st yr of RRT
• SCD risk is > for HD than PD patients during 1st 6 months of dialysis, but equalizes thereafter
0
10
20
30
40
50
60
70
eventrate per1000 yrs
General
CKD
Dialysis
Karnik JA et al (Kidney International 2001:60:350-357) : Characteristics associated with arrest on hemodialysis
– Monday or Tuesday (greatest risk last 12 hrs before dialysis)
– Low potassium dialysate – Older age – Diabetic – Catheter for access
CKD and SCD
• In ESRD pts Inc in SCD p long interHD periods
• Causes (?Hyperkalemia, ?Fluid XS, ?Low K/Ca baths)
• High prevalence of CMO, LVH, Hyperkalemia, Fluid Overlad and Long QT
• Treatment: BB and AICD all not studied well
0
10
20
30
40
50
60
70
80
50-75 25-50 <25 Dialysis
Creatinine clearance (mL/min)
Pre
vale
nce o
f L
VH
(%
)
p <0.003 (trend
analysis)
Prevalence of Left Ventricular Hypertrophy in Relation to Creatinine Clearance
Patients with diabetes = 24%
Adapted from Levin A et al. Am J Kidney Dis 1999; 34: 125-34.
n = 246
CKD and CVD
• In Conclusion there is paucity of data here
• ESRD pts are usually excluded from trials
and have a high mortality over a short time
frame complicating our ability to study and
recruit these most vulnerable pts
• Thus the Txs for non ESRD pts should be used
for ESRD pts and further work is needed
Cumulative probability of a physician visit at month 12 after CKD
diagnosis, by dataset & physician specialty: all CKD Figure 3.5 (Volume 1)
Medicare (age 66 & older)
& MarketScan & Ingenix i3
(age 50–64) patients with
CKD identified in 2007.
CKD patients are receiving most of their care from their PCP
USRDS Annual Data Report 2011
Timely Referral Leads to Reduced
Mortality
0%
10%
20%
30%
40%
On
e Y
ea
r M
orta
lity
Ra
te
< 1 month 1-4 mos > 4 mosTiming of Referral to
Nephrologist
(Time Prior to Start of
Dialysis)
Impact of Timing of Referral to
Nephrologist on Mortality
Early Referral Late Referral
90 Day Mortality 3 3% 13%
6 Month Mortality 4 13% 31%
1 Year Mortality 5 6% 39%
1 Year Mortality 2 22% 41%
2 Year Mortality 6 56% 69%
2
5
In a Recent Study of 300 Medicare Beneficiaries,
the Risk of Death in the First Year on Dialysis
Was Reduced by 48% For Early Referral
Patients Compared to Late Referral Patients. 2
Several Other Studies Shown Below Confirm
This.